Fox R M
Ludwig Institute for Cancer Research, University of Sydney, New South Wales, Australia.
Clin Exp Pharmacol Physiol Suppl. 1979;5:43-5.
The use of high dose methotrexate therapy in the treatment of malignant disease has been complicated by nephrotoxicity. Analysis of the basic physico-chemical properties of methotrexate has allowed the development of improved techniques of administering methotrexate, at high dose, which greatly reduces the incidence of nephrotoxicity.
